The journey to introduce a groundbreaking healing mushroom to the world will carry on. Ahead of the Season 1 finale this Sunday, Adult Swim has confirmed that Common Side Effects has been renewed for a second season.
This animated comedic thriller, co-created by Joe Bennett (Scavengers Reign) and Steve Hely (Veep), and executive produced by Mike Judge and Greg Daniels (King of the Hill), delves into the aftermath of the discovery of a mysterious, life-changing mushroom.
“Joe and Steve did their job by crafting a boundary-pushing and genre-defining piece of television that re-frames what ‘adult animation’ is capable of,” said Adult Swim president Michael Ouweleen. “And you all did your job by showing up on Adult Swim and Max to support the show and lighting up your socials to spread the word. So, see? We CAN have nice things.”
The half-hour series centers around Marshall and Frances, two former high school lab partners who share a remarkable secret: Marshall has discovered the world’s most extraordinary medicine, a mushroom with the ability to heal nearly anything. However, the path to introducing it to the world is fraught with obstacles, as the DEA, big pharma, and global businessmen are all trying to stop them.
The show features the voices of Joseph Lee Anderson, Mike Judge, Martha Kelly, Dave King, and Emily Pendergast.
“We are grateful for the enthusiastic response to Common Side Effects and are thrilled to continue exploring this world with our amazing team and the fans who have embraced the show,” said co-creators Bennett and Hely. “The opportunity to push the boundaries of animation and storytelling on Adult Swim is like a wonderful mushroom dream. Our goal with the show is to transform planet Earth and restore the human spirit. For now, we will settle for a second season.”
The Season 1 finale of Common Side Effects will air this Sunday at 11:30 PM ET/PT on Adult Swim.
Produced for Adult Swim by Bandera Entertainment and Green Street Pictures, Common Side Effects will return for more adventures in Season 2.
